PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33385372-1	2021	In the present study, Death receptor-5 (DR5) antibody conjugated solid lipid nanoparticles (DR5-DAPT-SLNs) has been formulated for effective intracellular of gamma-secretase inhibitor, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) to cancer cells.	dapt	185-254	TNF receptor superfamily member 10b	Homo sapiens	22-38	
33385372-1	2021	In the present study, Death receptor-5 (DR5) antibody conjugated solid lipid nanoparticles (DR5-DAPT-SLNs) has been formulated for effective intracellular of gamma-secretase inhibitor, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) to cancer cells.	dapt	185-254	TNF receptor superfamily member 10b	Homo sapiens	40-43	
33385372-1	2021	In the present study, Death receptor-5 (DR5) antibody conjugated solid lipid nanoparticles (DR5-DAPT-SLNs) has been formulated for effective intracellular of gamma-secretase inhibitor, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) to cancer cells.	dapt	185-254	TNF receptor superfamily member 10b	Homo sapiens	92-95	
33385372-1	2021	In the present study, Death receptor-5 (DR5) antibody conjugated solid lipid nanoparticles (DR5-DAPT-SLNs) has been formulated for effective intracellular of gamma-secretase inhibitor, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) to cancer cells.	dapt	96-100	TNF receptor superfamily member 10b	Homo sapiens	22-38	
33385372-1	2021	In the present study, Death receptor-5 (DR5) antibody conjugated solid lipid nanoparticles (DR5-DAPT-SLNs) has been formulated for effective intracellular of gamma-secretase inhibitor, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) to cancer cells.	dapt	96-100	TNF receptor superfamily member 10b	Homo sapiens	40-43	
33385372-1	2021	In the present study, Death receptor-5 (DR5) antibody conjugated solid lipid nanoparticles (DR5-DAPT-SLNs) has been formulated for effective intracellular of gamma-secretase inhibitor, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) to cancer cells.	dapt	96-100	TNF receptor superfamily member 10b	Homo sapiens	92-95	
33385372-6	2021	DR5-DAPT-SLNs have higher cytotoxicity in MDA-MB231 cells compared to DAPT-SLNs (non-targeted) and the bulk drug.	dapt	4-8	TNF receptor superfamily member 10b	Homo sapiens	0-3	
33385372-8	2021	The above results, therefore, demonstrate DR5 mediated uptake is responsible for improved cytotoxicity of DAPT.	dapt	106-110	TNF receptor superfamily member 10b	Homo sapiens	42-45	
33385372-9	2021	In the in vivo anticancer study, DR5-DAPT-SLNs show greater tumor regression when compared to DAPT-SLNs and the bulk drug.	dapt	37-41	TNF receptor superfamily member 10b	Homo sapiens	33-36	
33385372-10	2021	In conclusion, the results of the present study demonstrate that the DR5-DAPT-SLNs selectively target cancer cells and potentiate the anticancer efficacy of DAPT against TNBC cells.	dapt	73-77	TNF receptor superfamily member 10b	Homo sapiens	69-72	
33385372-10	2021	In conclusion, the results of the present study demonstrate that the DR5-DAPT-SLNs selectively target cancer cells and potentiate the anticancer efficacy of DAPT against TNBC cells.	dapt	157-161	TNF receptor superfamily member 10b	Homo sapiens	69-72